News

Virginia Catalyst Awards $3.2 Million in Grants to Support Life Sciences in the Commonwealth

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These projects were awarded in Grant Round 17.

“The Catalyst works to help industry partners and academic investigators to raise follow-on funding” said Mike Grisham, CEO of Virginia Catalyst. Through this 17th round of funding, Virginia Catalyst has awarded 69 grants totaling over $36 million, resulting in over $54 million in matching funds and over $700 million in follow-on funding to date.

The Virginia Catalyst in now accepting Letters of Intent for Grant Round 18, until March 14th.
For more information visit: https://www.VirginiaCatalyst.org/apply.html

Grant Round 17 project awardees:

Project: Adenosine A2B receptor blockade for the treatment of Clostridium difficile infection (CDI) •Company: Adovate, LLC (Charlottesville, VA)
•University collaborators: University of Virginia and Virginia Tech
•Funding amount: $800,000

Project: Anti-bioflim enzyme (ABE) as a novel, non-toxic solution that overcomes antimicrobial resistance to protect human health from farm to fork
• Company: Lytos Technologies, LLC (Charlottesville, VA)
•University collaborators: University of Virginia and Virginia Tech
•Funding amount: $800,000

Project: Orthopaedic Surgical Site Infection Prevention via an Antibiotic Releasing Click Hydrogel
•Company: Pascal Medical Corporation (Richmond, VA)
•University collaborators: Virginia Commonwealth University and George Mason University
•Funding amount: $800,000

Project: Investigational New Drug Enabling Studies of STX2310
•Company: S1P Therapeutics Inc. (Blacksburg, VA)
•University collaborators: Virginia Tech and University of Virginia
•Funding amount: $800,000

 

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital